Paion hands over rest of desmoteplase rights to Lundbeck
This article was originally published in Scrip
Executive Summary
Cash-strapped Paion has sold all its remaining rights to clot-busting drug candidate desmoteplase to Lundbeck for €20 million, "completely abandoning the high-risk area of stroke and exposure to the success of desmoteplase", said the German firm.